Tag Archives: psychiatrist

Dementia diagnosis

GPs may struggle to distinguish between people who have dementia and those with other conditions, says a new study.

It’s easy for us mere mortals to assume a lapse in memory is an early sign of dementia, but more disturbing is a new report that finds that GPs may also get it wrong.

Researchers from the University of Leicester and colleagues from Germany looked at data of more than 15,000 individuals who consulted doctors because of suspected cognitive disorders. Of those, 7109 had been assessed specifically for dementia. As they analysed the data, they found that GPs successfully identified eight out of 10 people with moderate to severe dementia, but were less accurate when it came to spotting early dementia – only 45% were correctly recognised as suffering with symptoms.

But the problem isn’t just that GPs may miss some of those who have early signs of dementia, they are also misdiagnosing some people who don’t have the illness. “This study highlights for the first time that GPs trying to identify dementia actually make more false positive errors, with misidentifications outnumbering missed cases at least two to one,” says psychiatrist Dr Alex Mitchell, of the University of Leicester. The incorrect diagnoses were more likely to occur where the person lived alone where no other informants were available. Those with depression or hearing problems were more likely to be identified as having dementia when they didn’t.

Dementia

Dementia

The solution, say the researchers, is to provide GPs with a simple cognitive screening test which would help them achieve about 90% accuracy.

Everyone occasionally forgets things, and some people are naturally more forgetful than others. Furthermore, if you’re stressed, tired, ill or trying to remember too many things at once, you’ll experience more forgetfulness.


Memory loss that indicates early dementia is more than simply walking into the kitchen and not being able to remember what you came for – that happens to everyone at one time or another – this is more a case of an inability to remember things affecting a person’s day-to-day life.

Disabling memory loss, where an individual finds him/herself unable to function well socially or finds themselves unsure of whether their front door is their own, is more likely to be an indicator of dementia.

Even then, however, memory lapses can exacerbated by many other factors such as reduction in blood flow to the brain caused by high blood pressure, lack of sleep and sleep apnoea, underactive thyroid, depression as well as medications that include memory problems as a side effect.

If you are concerned about yourself or someone you know, you can ask your GP to give you a clinical assessment, which may include the General Practitioner Assessment of Cognition; the Mini Mental State Examination; or the 6 Item Cognitive Impairment Test.

Alzheimer’s screening within two years

All pensioners could be screened for signs of Alzheimer’s within two years.

Advances in science mean there is a range of blood, brain and memory tests capable of picking up dementia in its earliest stages.

By 2013, they could be in use in GPs’ surgeries, allowing anyone over 65 with dangerous memory lapses to be treated when it will help them the most.

Excitingly, within just five to ten years, we should have drugs that will stop Alzheimer’s in its tracks – meaning those caught early through screening need never go on to suffer the cruel disease.

Even delaying the onset of Alzheimer’s by five years could halve the number who die with the condition, currently a third of over-65s.

Alzheimer’s and other forms of dementia affect more than 800,000 Britons, and the number is expected to double in a generation.

Speaking at the launch of an international drive to improve the treatment of mental health disorders, Barbara Sahakian, a professor at Cambridge University’s psychiatry department, said routine screening would end the ‘tragedy’ of people being diagnosed with the disease too late.

Currently, a third of cases of dementia go undiagnosed and untreated – but in some areas the figure is as high as 74 per cent.

And many of those who do get a diagnosis don’t get it until relatively late in the progression of the disease.

Alzheimer's

Alzheimer's

Professor Sahakian said: ‘I am shocked some people are allowed to deteriorate so much and then finally someone figures out that they probably have Alzheimer’s disease and takes them to the GP and psychiatrist. By that time the drugs don’t work as effectively. It is tragic.’

Current diagnosis is usually based on memory tests. But with sample questions including ‘where are you?’ and ‘who is prime minister?’ they are of little use in catching the disease early, said the professor.

Around the world, including Britain, tests are being developed that spot signs of the disease in the blood.

One, being developed at Proteome Sciences at King’s College London, uses a pinprick of blood. Other tests pick up changes in the brain, the eyes, or use computer-based games to test memory.

Professor Sahakian has developed a memory test that could be done on a laptop in a GP’s surgery in just ten minutes and distinguish between normal forgetfulness and the lapses that are likely to turn into Alzheimer’s.

She said many of the tests are ‘good to go’ and it now needs to be worked out which work best and if they are better used alone or in combination. This could take two years – after which screening could be introduced.

Initially, those with potentially dangerous memory lapses could be prescribed existing Alzheimer’s drugs such as Aricept.


While they do not halt the march of the disease, they can improve attention and concentration, allowing patients in the very early stages of dementia to stay at work and maintain a normal life for longer.

But, with several companies developing ‘neuroprotective’ medicines that could stop Alzheimer’s in its tracks, in time, it may be possible to stop people from ever developing the disease.

The professor – part of a global taskforce who list early dementia diagnosis as one of the 25 top challenges in mental health medicine in a commentary in the journal Nature this week – said: ‘To some extent it depends on the side-effects.

‘If they don’t have many side-effects, they’ll be available within five years. But if they have to do more work on reducing side-effects, it will be ten years. If there is a neuroprotective agent and it stops the disease process, then presumably you would die of something else, it wouldn’t be Alzheimer’s disease.’

Rebecca Wood, of Alzheimer’s Research UK, cautioned: ‘It’s possible that screening could improve diagnosis rates – however, screening for any disease is controversial. We need more research to assess whether a screening programme could really help, or whether it would produce falsely positive or negative results.’

The Alzheimer’s Society said the charity was funding research into treatments that give benefits five times longer than current dementia drugs.